| High grade serous ovarian carcinomas originate in the fallopian tube SI Labidi-Galy, E Papp, D Hallberg, N Niknafs, V Adleff, M Noe, ... Nature communications 8 (1), 1093, 2017 | 609 | 2017 |
| Long term performance of polycaprolactone vascular grafts in a rat abdominal aorta replacement model S de Valence, JC Tille, D Mugnai, W Mrowczynski, R Gurny, M Möller, ... Biomaterials 33 (1), 38-47, 2012 | 428 | 2012 |
| Degradation and healing characteristics of small-diameter poly (ε-caprolactone) vascular grafts in the rat systemic arterial circulation E Pektok, B Nottelet, JC Tille, R Gurny, A Kalangos, M Moeller, ... Circulation 118 (24), 2563-2570, 2008 | 413 | 2008 |
| Lymphangiogenesis and tumor metastasis MS Pepper, JC Tille, R Nisato, M Skobe Cell and tissue research 314 (1), 167-177, 2003 | 275 | 2003 |
| First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours I Van der Auwera, Y Cao, JC Tille, MS Pepper, DG Jackson, SB Fox, ... British journal of cancer 95 (12), 1611-1625, 2006 | 270 | 2006 |
| αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro RE Nisato, JC Tille, A Jonczyk, SL Goodman, MS Pepper Angiogenesis 6, 105-119, 2003 | 246 | 2003 |
| Factorial design optimization and in vivo feasibility of poly(ε‐caprolactone)‐micro‐ and nanofiber‐based small diameter vascular grafts B Nottelet, E Pektok, D Mandracchia, JC Tille, B Walpoth, R Gurny, ... Journal of Biomedical Materials Research Part A: An Official Journal of The …, 2009 | 206 | 2009 |
| Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF-and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro JC Tille, J Wood, SJ Mandriota, C Schnell, S Ferrari, J Mestan, Z Zhu, ... Journal of Pharmacology and Experimental Therapeutics 299 (3), 1073-1085, 2001 | 171 | 2001 |
| Advantages of bilayered vascular grafts for surgical applicability and tissue regeneration S De Valence, JC Tille, JP Giliberto, W Mrowczynski, R Gurny, ... Acta biomaterialia 8 (11), 3914-3920, 2012 | 140 | 2012 |
| Plasma treatment for improving cell biocompatibility of a biodegradable polymer scaffold for vascular graft applications S de Valence, JC Tille, C Chaabane, R Gurny, ML Bochaton-Piallat, ... European Journal of Pharmaceutics and Biopharmaceutics 85 (1), 78-86, 2013 | 113 | 2013 |
| Porcine carotid artery replacement with biodegradable electrospun poly-e-caprolactone vascular prosthesis W Mrówczyński, D Mugnai, S de Valence, JC Tille, E Khabiri, ... Journal of vascular surgery 59 (1), 210-219, 2014 | 107 | 2014 |
| Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C K Persaud, JC Tille, M Liu, Z Zhu, X Jimenez, DS Pereira, HQ Miao, ... Journal of Cell Science 117 (13), 2745-2756, 2004 | 107 | 2004 |
| Expression and localization of VEGF‐C and VEGFR‐3 in glioblastomas and haemangioblastomas B Jenny, JA Harrison, D Baetens, JC Tille, K Burkhardt, H Mottaz, JZ Kiss, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2006 | 106 | 2006 |
| Lymphangiogenesis and tumor metastasis RE Nisato, JC Tille, MS Pepper Thrombosis and haemostasis 90 (10), 591-597, 2003 | 96 | 2003 |
| Thyroid Pathology in PTEN-Hamartoma Tumor Syndrome: Characteristic Findings of a Distinct Entity AR Laury, M Bongiovanni, JC Tille, H Kozakewich, V Nosé Thyroid 21 (2), 135-144, 2011 | 87 | 2011 |
| Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes S De Talhouet, J Peron, A Vuilleumier, A Friedlaender, V Viassolo, ... Scientific reports 10 (1), 7073, 2020 | 85 | 2020 |
| Paclitaxel-eluting biodegradable synthetic vascular prostheses: a step towards reduction of neointima formation? F Innocente, D Mandracchia, E Pektok, B Nottelet, JC Tille, S de Valence, ... Circulation 120 (11_suppl_1), S37-S45, 2009 | 83 | 2009 |
| Mesenchymal cells potentiate vascular endothelial growth factor-induced angiogenesis in vitro JC Tille, MS Pepper Experimental cell research 280 (2), 179-191, 2002 | 83 | 2002 |
| Hereditary vascular anomalies: new insights into their pathogenesis JC Tille, MS Pepper Arteriosclerosis, thrombosis, and vascular biology 24 (9), 1578-1590, 2004 | 81 | 2004 |
| Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast M Lavigne, E Menet, JC Tille, M Lae, L Fuhrmann, C Bonneau, ... Modern Pathology 31 (1), 68-82, 2018 | 80 | 2018 |
